written on 23.05.2014

Teva and Active Biotech not giving up on EU-spurned MS treatment


The EU's Committee for Medicinal Products for Human Use (CHMP) is sticking to its opinion to recommend against approval of Teva and Active Biotech's MS drug Nerventra. But the companies aren't giving up, announcing Friday that they remain committed to the clinical development program and plan to evaluate CHMP's feedback before they plot out their next steps.